April 2011 in “Cancer Research” 20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.
January 2011 in “Zhonghua zhongyiyao xuekan” Yiqi Huayu medicine can effectively reduce BPH in rats by lowering MMP-2 levels and blood vessel growth.
September 2010 in “European Urology Supplements” PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.
September 2010 in “European Urology Supplements” Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.
August 2010 in “Oncology Times” Provenge extends prostate cancer survival by about 4 months.
June 2010 in “Journal of Chemical Crystallography” The compound was successfully made and shows potential for treating prostate cancer.
February 2010 in “Journal of The American Academy of Dermatology” Methotrexate treatment for rheumatoid arthritis has a serious infection rate of about two per 100 patient-years.
January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
September 2009 in “European Urology Supplements” After prostate removal surgery, higher initial prostate size was linked to higher urethral PSA levels and more severe male pattern baldness.
March 2009 in “The Journal of Urology” Low dose finasteride causes only small changes in PSA levels in older men with BPH.
March 2009 in “The Journal of Urology” Finasteride improves urinary symptoms and quality of life in BPH patients, especially with larger prostate size.
March 2009 in “The Journal of Urology” Shorter PSADT after prostate surgery is linked to higher risk of death.
January 2009 in “Journal of Jilin Medical College” SDG helps reduce BPH effects in rats.
November 2007 in “Cancer Epidemiology and Prevention Biomarkers” Higher C-peptide levels in African-American men and higher HbA1c levels in Caucasian men are linked to lower PSA levels.
PLX, a tomato extract mix, may help treat prostate issues like BPH.
research TOC
June 2007 in “Endocrinology and Metabolism Clinics of North America” The document covers various male health issues, their causes, treatments, and related conditions.
May 2007 in “The Journal of Urology” Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.
February 2007 in “Journal watch” Low-dose finasteride lowers PSA levels, which can make prostate cancer harder to detect.
October 2006 in “Urology” Combination therapy with Finasteride is more effective than alpha-blocker alone for BPH symptoms in small prostate volume.
October 2006 in “Urology” The document aimed to understand how certain treatments affect blood vessel growth in rat prostates.
October 2006 in “Aging Health” Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.
February 2006 in “Mayo Clinic Proceedings” Finasteride reduces prostate cancer risk but may increase high-grade cancer cases.
September 2004 in “Urology” Finasteride may reduce prostate cancer risk.
January 2004 in “Anticancer Research” Long-term antiandrogen use may increase aggressive prostate cancer risk.
August 2003 in “Oncology Times” The trial on testosterone replacement therapy in older men faced concerns due to prostate cancer risk.
April 2003 in “Experimental Dermatology” The workshop highlighted the genetic links and psychological impacts of hair loss and skin disorders.
February 2003 in “European Urology Supplements” Baseline PSA levels affect general health and sexual satisfaction in men with BPH treated with finasteride or placebo.
May 1999 in “Drugs & Therapy Perspectives” Finasteride helps increase or maintain hair in most men but can cause sexual side effects and should not be used by women, especially during pregnancy.
February 1999 in “Strength and Conditioning Journal” Androstenedione, a hormone supplement, doesn't improve muscle or performance and can cause harmful side effects.
December 1998 in “Acta Crystallographica Section C-crystal Structure Communications” A new compound with strong antiandrogenic effects was found, potentially useful for treating conditions like acne and prostate cancer.